Interim Results in ALLOB Phase IIA Spinal Fusion Study

Results from the first 15 patients in a Phase IIA trial with Bone Therapeutics' ALLOB® show evidence of successful spinal fusion and statistically significant improvements at 12 months.

The trial is evaluating the use of ALLOB allogeneic cell therapy along with the standard of care: implantation of an interbody cage + bioceramic granules.

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us